Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 2/20 | 0.40 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | BRD2 | P25440 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12658975 | 0.94 | GRIN1 (0.38) | GRIN1GRIN2ABRD4BRD2OPRM1 | |
| SCHEMBL27046535 | 0.87 | GRIN1 (0.41) | GRIN1GRIN2ABRD4BRD2OPRM1 | |
| SCHEMBL17207551 | 0.85 | GRIN1 (0.38) | GRIN1GRIN2ABRD4BRD2 | |
| SCHEMBL12658967 | 0.77 | GRIN1 (0.33) | GRIN1GRIN2ABRD4BRD2 | |
| SCHEMBL24112202 | 0.71 | GRIN2B (0.53) | — | |
| SCHEMBL13460109 | 0.71 | GRIN1 (0.40) | GRIN1GRIN2ABRD4BRD2 | |
| SCHEMBL15187451 | 0.71 | BRD4 (0.32) | GRIN1GRIN2ABRD4BRD2 | |
| SCHEMBL30310678 | 0.70 | GRIN2B (0.39) | — | |
| SCHEMBL26456980 | 0.70 | GRIN1 (0.42) | GRIN1GRIN2ABRD4BRD2 | |
| SCHEMBL21238807 | 0.69 | GRIN1 (0.33) | GRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSL, CTSV | GRIN1 4639/4885GRIN2A 4615/4885BRD4 3186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.